Table e-3: Sleep parameters in male and female subjects

|  |  |  |
| --- | --- | --- |
| Mean (SD) | Placebo(N=54) | Daridorexant |
| 5 mg(N=56) | 10 mg(N=54) | 25 mg(N=55) | 50 mg(N=56) |
| Male(n=18) | Female(n=36) | Male(n=19) | Female(n=37) | Male(n=18) | Female(n=36) | Male(n=19) | Female(n=36) | Male(n=18) | Female(n=38) |
| **Primary endpoint**  |  |  |  |  |  |  |  |  |  |  |
| WASO, min |  |  |  |  |  |  |  |  |  |  |
| Baseline | 129.5 (35.9) | 111.7(40.6) | 124.5(41.2) | 112.7(40.4) | 129.5(35.9) | 111.7(40.6) | 124.5(41.2) | 111.7(40.6) | 129.5(35.9) | 110.0(40.6) |
| Change at Days 1&2 | –12.6(42.7) | –14.9(48.5) | –20.7(39.6) | –17.3(54.7) | –28.7(29.6) | –34.2(42.5) | –41.8(46.5) | –45.5(45.2) | –65.9(30.4) | –58.8(46.9) |
| **Secondary endpoint** |  |  |  |  |  |  |  |  |  |  |
| LPS |  |  |  |  |  |  |  |  |  |  |
| Baseline | 76.1(59.6) | 73.4(43.7) | 83.1(65.3) | 72.3(43.6) | 76.1(59.6) | 73.4(43.7) | 83.1(65.3) | 73.4(43.7) | 76.1(59.6) | 73.1(43.0) |
| Change at Days 1&2 | –32.6(48.8) | –34.5(38.5) | –52.8(59.4) | –30.3(41.1) | –44.5(52.0) | –44.7(35.6) | –42.9(52.3) | –45.8(35.5) | –47.8(57.2) | –43.5(37.4) |
| **Other efficacy endpoints** |  |  |  |  |  |  |  |  |  |  |
| sWASO |  |  |  |  |  |  |  |  |  |  |
| Baseline | 107.4(48.5) | 94.7(73.5) | 110.4(49.0) | 95.7(72.8) | 107.4(48.5) | 94.7(73.5) | 110.4(49.0) | 94.7(73.5) | 107.4(48.5) | 95.2(71.6) |
| Change at Days 1&2 | –14.4(48.6) | –9.1(79.0) | –31.0(52.2) | –12.4(77.6) | –32.4(44.4) | –21.6(70.2) | –41.0(53.8) | –37.0(67.8) | –41.8(45.6) | –35.8(77.7) |
| sLSO |  |  |  |  |  |  |  |  |  |  |
| Baseline | 66.9(43.7) | 64.4(43.5) | 70.5(45.2) | 63.8(43.1) | 66.9(43.7) | 64.4(43.5) | 70.5(45.2) | 64.4(43.5) | 66.9(43.7) | 64.8(42.6) |
| Change at Days 1&2 | –19.4(33.8) | –11.2(41.8) | –27.2(33.4) | –8.5(26.1) | –22.6(32.5) | –23.9(32.1) | –25.8(28.8) | –21.6(34.1) | –33.5(24.0) | –23.8(39.3) |
| TST, min |  |  |  |  |  |  |  |  |  |  |
| Baseline | 282.9(49.9) | 302.2(60.8) | 281.0(49.1) | 302.3(59.9) | 282.9(49.9) | 302.2(60.8) | 281.0(49.1) | 302.2(60.8) | 282.9(49.9) | 304.5(61.3) |
| Change at Days 1&2 | 44.4(38.6) | 44.8(51.5) | 70.6(46.9) | 45.3(59.9) | 69.7(37.5) | 76.2(54.4) | 85.8(39.8) | 88.5(51.9) | 115.4(41.5) | 100.0(56.3) |
| sTST, min |  |  |  |  |  |  |  |  |  |  |
| Baseline | 304.3(57.7) | 300.5(69.2) | 304.9(56.1) | 299.7(68.4) | 304.3(57.7) | 300.5(69.2) | 304.9(56.1) | 300.5(69.2) | 304.3(57.7) | 300.3(67.3) |
| Change at Days 1&2 | 28.8(50.5) | 34.8(78.2) | 28.8(59.0) | 26.1(71.8) | 28.6(58.6) | 57.1(68.8) | 47.3(50.0) | 60.8(61.9) | 72.5(44.7) | 68.1(79.1) |

Days 1&2 refers to the mean value of the corresponding two PSG treatment nights for a given treatment period.

LPS, latency to persistent sleep; SD, standard deviation; sLSO, subjective latency to sleep onset; sTST, self-reported total sleep time; sWASO, subjective wake after sleep onset; TST, total sleep time; WASO, wake after sleep onset.